AT

AptarGroup, Inc.

ATRHealthcareNASDAQ

Medical Instruments & Supplies

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$3.78B
+5.4% YoY
Net Income
$392.8M
+4.9% YoY
EBITDA
$831.5M
+6.9% YoY
Free Cash Flow
$253.0M

Scan Results

Daily timeframe
5 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Jul 11CONFIRMED Above MA150+0.6% from MA150, price crossed above
Above MA200+0.7% from MA200, price crossed above
Jul 10CONFIRMED Below MA2000.1% below MA200
Below MA1500.2% below MA150
About AptarGroup, Inc.

Part of the healthcare sector, AptarGroup, Inc. (ATR) is listed under Medical Instruments & Supplies. The company carries a $8.46B market cap, placing it firmly in the mid-cap category. The company operates through three segments: Pharma, Beauty, and Closures.

Key stats
Market Cap$8.46B
P/E (TTM)23.10
Fwd P/E21.21
EPS$5.74
Beta0.39
52W Change-15.2%
Dividend Yield1.40%
ROE14.8%
Analysis

The company holds $229.5M in cash, though total debt stands at $1.44B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $253.0M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 14.8%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 6.6% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $3.32B to $3.78B.

The relatively low beta of 0.39 suggests ATR is a less volatile holding compared to the broader index. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ATR.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance is an educational tool. Past performance does not guarantee future results.PrivacyTerms